Gian Marco Leggio

Gian Marco Leggio

Auto-generated profile, based on publicly available information

Gian Marco Leggio

Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, Catania University, Catania, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2012 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSalvatore Salomone
Salvatore Salomone
FCFilippo Caraci
Filippo Caraci
GLGian Marco Leggio
Gian Marco Leggio
JFJulia Fedotova
Julia Fedotova
Filippo DragoFilippo Drago
Filippo Drago

25 June 2008 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
VMVincenzo Micale
Vincenzo Micale
LCLuigia Cristino
Luigia Cristino
ATAlessandra Tamburella
Alessandra Tamburella
SPStefania Petrosino
Stefania Petrosino
GLGian Marco Leggio
Gian Marco Leggio
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo
The endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), and the transient receptor potential vanilloid type-1 (TRPV1) channel are new targets for the development of anxiolytic drugs. We studied the effect on anxiety-like behavior in the elevated plus maze of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT). In male C57BL/6J mice, acute intraperitoneal administration of AA-5-HT (0.1–2.5 mg/kg) increased both the time spent and the number of entries in the open arm, while being inactive at the highest dose tested (5 mg/kg). AA-5-HT was more potent than selective blockers of FAAH or TRPV1 (URB597 and SB366791, respectively). In male Swiss mice, AA-5-HT had to be administered chronically to observe an anxiolytic effect at an intermediate dose (2.5 mg/kg), the highest dose (5 mg/kg) being anxiogenic, and 1 mg/kg being ineffective. In both strains, the anxiolytic effects of AA-5-HT were paralleled by elevation of brain endocannabinoid levels and were reversed by per se inactive doses of the cannabinoid receptors of type-1 (CB1) receptor antagonist AM251, or the TRPV1 agonist, olvanil. Immunohistochemical localization of CB1 and TRPV1 receptors was observed in mouse prefrontal cortex, nucleus accumbens, amygdala, and hippocampus. Simultaneous ‘indirect’ activation of CB1 receptors following FAAH inhibition, and antagonism at TRPV1 receptors might represent a new therapeutic strategy against anxiety.

1 November 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
GLGian Marco Leggio
Gian Marco Leggio
SSSalvatore Salomone
Salvatore Salomone
Claudio BucoloClaudio Bucolo
Claudio Bucolo
Chiara B. M. PlataniaChiara B. M. Platania
Chiara B. M. Platania
VMVincenzo Micale
Vincenzo Micale
Filippo DragoFilippo Drago
Filippo Drago

1 October 2010 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MAM. Amadio
M. Amadio
Claudio BucoloClaudio Bucolo
Claudio Bucolo
GLG.M. Leggio
G.M. Leggio
Filippo DragoFilippo Drago
Filippo Drago
SGStefano Govoni
Stefano Govoni
APA. Pascale
A. Pascale

6 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Chiara B. M. PlataniaChiara B. M. Platania
Chiara B. M. Platania
SSSalvatore Salomone
Salvatore Salomone
GLGian Marco Leggio
Gian Marco Leggio
Filippo DragoFilippo Drago
Filippo Drago
Claudio BucoloClaudio Bucolo
Claudio Bucolo
Dopamine (DA) receptors, a class of G-protein coupled receptors (GPCRs), have been targeted for drug development for the treatment of neurological, psychiatric and ocular disorders. The lack of structural information about GPCRs and their ligand complexes has prompted the development of homology models of these proteins aimed at structure-based drug design. Crystal structure of human dopamine D3 (hD3) receptor has been recently solved. Based on the hD3 receptor crystal structure we generated dopamine D2 and D3 receptor models and refined them with molecular dynamics (MD) protocol. Refined structures, obtained from the MD simulations in membrane environment, were subsequently used in molecular docking studies in order to investigate potential sites of interaction. The structure of hD3 and hD2L receptors was differentiated by means of MD simulations and D3 selective ligands were discriminated, in terms of binding energy, by docking calculation. Robust correlation of computed and experimental Ki was obtained for hD3 and hD2L receptor ligands. In conclusion, the present computational approach seems suitable to build and refine structure models of homologous dopamine receptors that may be of value for structure-based drug discovery of selective dopaminergic ligands.

3 March 2014 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
GLGian Marco Leggio
Gian Marco Leggio
GCGiovanni Camillieri
Giovanni Camillieri
Chiara B. M. PlataniaChiara B. M. Platania
Chiara B. M. Platania
Alessandro CastorinaAlessandro Castorina
Alessandro Castorina
GMGiuseppina Marrazzo
Giuseppina Marrazzo
SSSalvatore Salomone
Salvatore Salomone
Mesolimbic dopamine (DA) controls drug- and alcohol-seeking behavior, but the role of specific DA receptor subtypes is unclear. We tested the hypothesis that D3R gene deletion or the D3R pharmacological blockade inhibits ethanol preference in mice. D3R-deficient mice (D3R−/−) and their wild-type (WT) littermates, treated or not with the D3R antagonists SB277011A and U99194A, were tested in a long-term free choice ethanol-drinking (two-bottle choice) and in a binge-like ethanol-drinking paradigm (drinking in the dark, DID). The selectivity of the D3R antagonists was further assessed by molecular modeling. Ethanol intake was negligible in D3R−/− and robust in WT both in the two-bottle choice and DID paradigms. Treatment with D3R antagonists inhibited ethanol intake in WT but was ineffective in D3R−/− mice. Ethanol intake increased the expression of RACK1 and brain-derived neurotrophic factor (BDNF) in both WT and D3R−/−; in WT there was also a robust overexpression of D3R. Thus, increased expression of D3R associated with activation of RACK1/BDNF seems to operate as a reinforcing mechanism in voluntary ethanol intake. Indeed, blockade of the BDNF pathway by the TrkB selective antagonist ANA-12 reversed chronic stable ethanol intake and strongly decreased the striatal expression of D3R. Finally, we evaluated buspirone, an approved drug for anxiety disorders endowed with D3R antagonist activity (confirmed by molecular modeling analysis), that resulted effective in inhibiting ethanol intake. Thus, DA signaling via D3R is essential for ethanol-related reward and consumption and may represent a novel therapeutic target for weaning.